报价延迟最少15分钟:2025/07/21 06:41 EDT
盘前时段
|
||||
|
7.31 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.54
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.53/-7.53
|
|
企业价值
208.50M
|
| 资产负债 |
|
每股账面净值
4.38
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
67.64M
|
|
每股收益
3.77
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 06:41 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline. |
